SRX

2.94%

17.5¢ sierra rutile holdings limited

Ann: Trading Halt, page-77

First 77 Last

Share
Profile

Follow
whytee

16,820 Posts.

2398

23/04/17

12:39

Post #: 24217905
Share

Originally posted by Southoz ↑

I have maybe a slightly different take Tran777.

The way I look at ITT and PP is the difference between efficacy and effectiveness.

I have a new drug. It tastes terrible. I run a trial.

Of the subjects that take the drug as they were supposed to (PP) they do very well. Trouble is many patients don’t take the drug as required and so don’t improve. Consequently the ITT analysis fails.

If the development process is at an early stage this might be a great result. The drug has efficacy and I can fix the taste to improve compliance and hence effectiveness later.

The interaction with ITT and PP with non-inferiority trials however is more subtle.

The first simple point is a failed superiority trial cant become a successful non-inferiority trial. Pretty well full stop at that point.

But secondly PP comparisons (and not ITT) analyses are used in non-inferiority trials because essentially you are reversing the bias.

Imagine you ran a hopeless non-inferiority trial and large numbers of patients in both groups didn’t even start or comply with their treatments. The more hopeless your study was the better for showing non-inferiority (no difference) between the two treatments.

For this reason you take the PP treatment groups and compare the (hopefully) overlapping margins on them. In my hopeless study example I will fail because my small Ns of those who actually complied will produce a large CI.

Here the situation is a little bit trickier between ITT and PP because it would be expected that subject compliance isn’t the issue rather it is patient switching out of treatments. And this is informative of outcome – patients switched because they weren’t doing well. This is the bug bear of oncology trials; the ethics of the life and death make things more complicated.

Expand

Indeed. I'm hopeful that SIRveNIB and FOXFIRE will provide sufficient evidence that patients can be better selected for a particular treatment based on the likelihood of success with that treatment.

This trial, like Sirflox, was designed to fail the primary end point.

SRX Price at posting: $17.00 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Bitcoin: Current State of Play & Where to Next | Swyftx

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

TNC

True North increases silver metal at QLD's Vero deposit by 20%

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

There are more pages in this discussion • 4 more messages in this thread...

First 77 Last

Add SRX (ASX) to my watchlist

(20min delay)
Last 17.5¢		Change 0.005(2.94%)		Mkt cap ! $74.27M

Open	High	Low	Value	Volume
17.5¢	18.0¢	17.5¢	$356.3K	2.036M

Buyers (Bids)

No.	Vol.	Price($)
1	85000	17.5¢

Sellers (Offers)

Price($)	Vol.	No.
18.0¢	2482400	31

View Market Depth

No.	Vol.	Price($)
1	85000	0.175
10	10413204	0.170
1	18186	0.165
1	2577	0.097
1	4000	0.075

Price($)	Vol.	No.
0.180	2287070	26
0.185	117915	7
0.190	128362	5
0.195	509604	3
0.200	185531	8

Last trade - 15.59pm 09/08/2024 (20 minute delay)

SRX (ASX) Chart

Ann: Trading Halt, page-77

Bitcoin: Current State of Play & Where to Next | Swyftx

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

True North increases silver metal at QLD's Vero deposit by 20%

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-77

Top Stories

Bitcoin: Current State of Play & Where to Next | Swyftx

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

True North increases silver metal at QLD's Vero deposit by 20%

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News